Navigation Links
Noninvasive tests for cirrhosis may help to avoid liver biopsy
Date:10/1/2007

Philadelphia, PA, October 1, 2007 Newer ultrasound and magnetic resonance (MR) imaging tests yield encouraging initial results in diagnosing fibrosis (scarring) and cirrhosis of the liver, according to three studies in the October issue of the journal Clinical Gastroenterology and Hepatology.

With further research, these and other non-invasive imaging techniques may reduce the need for biopsiesprocedures done to obtain a tissue sampleto determine the presence and severity of fibrosis and cirrhosis.

Two of the three new papers evaluated techniques of elastographytests that evaluate reactions to ultrasound vibrations or energy waves as a means of measuring the elasticity or stiffness of the liver tissue. Lower elasticity (or higher stiffness) corresponds to increased fibrosis or scarring. When fibrosis becomes severe, it signals the presence of cirrhosis.

Dr. Jayant A. Talwalkar and colleagues of Mayo Clinic College of Medicine, Rochester, Minn., analyzed the current evidence on ultrasound-based transient elastographythe approach that has received the most research attention to date. Based on data from 18 previous studies, the ultrasound test was highly accurate in identifying patients with cirrhosis, defined as severe (stage IV) fibrosis of the liver. About 90 percent of patients with cirrhosis were correctly identified by ultrasound-based transient elastography. The test was somewhat less accurate in detecting less-severe fibrosis.

Because the studies used differing cutoff points, the analysis could not establish the true accuracy of this emerging technology. The researchers highlight the need for additional high-quality studies including patients with liver fibrosis ranging from mild to severe.

Dr. Meng Yin and colleagues, also of Mayo Clinic College of Medicine, evaluated a different approach to measuring liver elasticity/stiffness: MR elastography. Although the principle is the same as with the ultrasound
'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
2. Gamma Knife Offers Noninvasive Treatment for Vascular Disorders, Brain Tumors
3. Hope for Noninvasive Prenatal Test
4. IMA wants members not to do sex determination tests during pregnancy
5. Doctors advice early anemia tests
6. Early diagnosis for autism from blood tests may be possible
7. FDA approves Phase 0 trial which tests experimental drugs on humans
8. Genetic tests for cancer
9. Space research leads to needle-free blood tests
10. The Effectiveness Of Screening Tests Questioned
11. Blood Tests Can Help Detect Osteoporosis Early In Life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...n. 8 New York City Mayor Michael R...Education Day" and presented a proclamation to Ilc...ucation Association) and developer of Brain Educat...to enhance health, well-being, and mental ability ... leader regarding the power of individuals to chan...
(Date:1/8/2009)...Va., Jan. 8 Today, the ...along with several national leadership organizatio...ciples of hospice care and protection of the Medic...gether in sharing this unified message about end-o...e and Palliative Medicine, Hospice and Palliative ...
(Date:1/8/2009)...ugar sitting on the surface of cancer cells are ke...th treating and stopping the spread of certain typ...state, breast, ovarian and lung, among others. Ar...e Gateway for Cancer Research, an Illinois-based p...ranco, M.D., Ph.D., and her co-workers at the Moor...
(Date:1/8/2009)...ts Prenatal Solution Key Factor in Decision for Fl...LANDO, Fla., Jan. 8 Alls...LC, one of the largest multi-specialty group pract...the Allscripts Enterprise(TM) Electronic Health Re...ians in 18 offices across Central Florida. , ,...
Breaking Medicine News(10 mins):Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4
...d test called Cystatin-C for predicting cardiovasc...malfunction. Earlier test that was used was creati...e more effective and better predictor than the ear...hree types of cardiovascular risks: low, medium an...
...erial infection of the lungs, says a study publish...rchers had studied persons of age between 2 to 49 ...rsons with invasive pneumococcal disease, 10 perso...as controls. Asthma was defined by the study as pr...
...ity Baptist Medical Center, US, have found that lo...hildren with cancer, and thus limits the side effe...oked into the chemotherapy given to children suffe...(ALL). Patients suffering from for this type of ch...
...accine for treating Alzheimer’s disease may be abl... use the bodies own immunity to resist the onset a...t affect people above the age of 40 years. The fi...ls which began some time back, was when scientists...
Other Medicine News:
(Date:1/7/2009)... , FREDERICK, Md., Jan. 7 ImQue...bmission of an IND application to the Food and Dru... for their lead pyrimidinedione HIV inhibitor IQP-... studies in the first quarter of 2009. IQP-0410 is...marily acts as a nonnucleoside reverse transcripta...
(Date:1/6/2009)... , Program Expands on Successful Results from p... Jan. 7 Vital Therapies, Inc. (VTI...ease, today announced patient enrollment has begun... 2 clinical trial that will study the Extracorpore...atients with Acute Liver Failure (ALF) under three...
(Date:1/6/2009)... , ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswir...utical company focused on diseases of epidemic pot...candidate for the treatment of tuberculosis (TB), ...wly awarded clinical program contract to Dynport V...e contract, awarded by the National Institute of A...
(Date:1/5/2009)... , SAN DIEGO, Jan. 5 Cylene Pha... a Phase I clinical trial of its oral CK2 protein ...ed solid tumors, Castleman,s disease, or multiple ...calating trial are determination of safety, tolera... appropriate dose for Phase II trials. In addition...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 1Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 2Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 3Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 4Sage Software Healthcare Appoints Kathleen Henry Senior Vice President Customer Service 32165 1Sage Software Healthcare Appoints Kathleen Henry Senior Vice President Customer Service 32165 2Immune System Works Better at Night 32164 1Immune System Works Better at Night 32164 2Later School Start Time Cuts Teens Car Crash Risk 32162 1Later School Start Time Cuts Teens Car Crash Risk 32162 2Later School Start Time Cuts Teens Car Crash Risk 32162 3
...)--Jun 4, 2007 - Introgen Therapeutics, Inc.,(NASD... today,reported updated Phase 2 data demonstrating...umor responses and increased,survival following AD...us cell carcinoma of the head and neck. The data (... meeting of the American,Society of Clinical Oncol...
...se 2 Clinical Data Published at the American,Socie...GO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmi...m its Phase II,multi-center clinical study of Amr...nthracycline currently in development,for the trea...dicate favorable interim results in terms of respo...
Other Medicine Technology:Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 2Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 3Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 4
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements.
Colour video monitors.
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty.
Camera and light source in one compact "Plug-and-Play" device.
Medicine Products: